Update on the use of immunoglobulin in human disease

A review of evidence

Elena E. Perez, Jordan S. Orange, Francisco Bonilla, Javier Chinen, Ivan K. Chinn, Morna Dorsey, Yehia El-Gamal, Terry O. Harville, Elham Hossny, Bruce Mazer, Robert Nelson, Elizabeth Secord, Stanley C. Jordan, E. Richard Stiehm, Ashley A. Vo, Mark Ballow

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.

Original languageEnglish (US)
Pages (from-to)S1-S46
JournalJournal of Allergy and Clinical Immunology
Volume139
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Immunoglobulins
Passive Immunization
Intravenous Immunoglobulins
Immune System
Therapeutics
Guidelines

Keywords

  • adverse events
  • autoimmunity
  • IGIV
  • Immune globulin
  • immune modulating
  • immunoglobulin
  • immunomodulation
  • IVIG
  • primary immunodeficiency
  • SCIG
  • transfusion

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., ... Ballow, M. (2017). Update on the use of immunoglobulin in human disease: A review of evidence. Journal of Allergy and Clinical Immunology, 139(3), S1-S46. https://doi.org/10.1016/j.jaci.2016.09.023

Update on the use of immunoglobulin in human disease : A review of evidence. / Perez, Elena E.; Orange, Jordan S.; Bonilla, Francisco; Chinen, Javier; Chinn, Ivan K.; Dorsey, Morna; El-Gamal, Yehia; Harville, Terry O.; Hossny, Elham; Mazer, Bruce; Nelson, Robert; Secord, Elizabeth; Jordan, Stanley C.; Stiehm, E. Richard; Vo, Ashley A.; Ballow, Mark.

In: Journal of Allergy and Clinical Immunology, Vol. 139, No. 3, 01.03.2017, p. S1-S46.

Research output: Contribution to journalArticle

Perez, EE, Orange, JS, Bonilla, F, Chinen, J, Chinn, IK, Dorsey, M, El-Gamal, Y, Harville, TO, Hossny, E, Mazer, B, Nelson, R, Secord, E, Jordan, SC, Stiehm, ER, Vo, AA & Ballow, M 2017, 'Update on the use of immunoglobulin in human disease: A review of evidence', Journal of Allergy and Clinical Immunology, vol. 139, no. 3, pp. S1-S46. https://doi.org/10.1016/j.jaci.2016.09.023
Perez, Elena E. ; Orange, Jordan S. ; Bonilla, Francisco ; Chinen, Javier ; Chinn, Ivan K. ; Dorsey, Morna ; El-Gamal, Yehia ; Harville, Terry O. ; Hossny, Elham ; Mazer, Bruce ; Nelson, Robert ; Secord, Elizabeth ; Jordan, Stanley C. ; Stiehm, E. Richard ; Vo, Ashley A. ; Ballow, Mark. / Update on the use of immunoglobulin in human disease : A review of evidence. In: Journal of Allergy and Clinical Immunology. 2017 ; Vol. 139, No. 3. pp. S1-S46.
@article{7741b57494d7459382e250c8f2bbf9f5,
title = "Update on the use of immunoglobulin in human disease: A review of evidence",
abstract = "Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.",
keywords = "adverse events, autoimmunity, IGIV, Immune globulin, immune modulating, immunoglobulin, immunomodulation, IVIG, primary immunodeficiency, SCIG, transfusion",
author = "Perez, {Elena E.} and Orange, {Jordan S.} and Francisco Bonilla and Javier Chinen and Chinn, {Ivan K.} and Morna Dorsey and Yehia El-Gamal and Harville, {Terry O.} and Elham Hossny and Bruce Mazer and Robert Nelson and Elizabeth Secord and Jordan, {Stanley C.} and Stiehm, {E. Richard} and Vo, {Ashley A.} and Mark Ballow",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.jaci.2016.09.023",
language = "English (US)",
volume = "139",
pages = "S1--S46",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Update on the use of immunoglobulin in human disease

T2 - A review of evidence

AU - Perez, Elena E.

AU - Orange, Jordan S.

AU - Bonilla, Francisco

AU - Chinen, Javier

AU - Chinn, Ivan K.

AU - Dorsey, Morna

AU - El-Gamal, Yehia

AU - Harville, Terry O.

AU - Hossny, Elham

AU - Mazer, Bruce

AU - Nelson, Robert

AU - Secord, Elizabeth

AU - Jordan, Stanley C.

AU - Stiehm, E. Richard

AU - Vo, Ashley A.

AU - Ballow, Mark

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.

AB - Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.

KW - adverse events

KW - autoimmunity

KW - IGIV

KW - Immune globulin

KW - immune modulating

KW - immunoglobulin

KW - immunomodulation

KW - IVIG

KW - primary immunodeficiency

KW - SCIG

KW - transfusion

UR - http://www.scopus.com/inward/record.url?scp=85009375131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009375131&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2016.09.023

DO - 10.1016/j.jaci.2016.09.023

M3 - Article

VL - 139

SP - S1-S46

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -